The purpose of the course is to further develop effective and sustainable pharmacovigilance in all countries by creating a unique opportunity for learning and collaboration. The participants will acquire necessary skills in collecting, coding and analysing individual case safety reports to detect medicine safety issues in their own settings.

Course outline
UMC pharmacovigilance course consists of pre-course online study, a two-week face-to-face course and a post-course follow up. The course focuses on topics essential to effective pharmacovigilance, including sessions about individual case safety report management, terminologies, causality assessment, signal detection and management work processes.

Pharmacovigilance experts from the WHO Headquarters, UMC and other well-known organizations will share their experience and knowledge in workshops, practical exercises and lectures. An important part of the course is mandatory pre-course online study which must be completed before the face-to-face course starts in May. This online study covers the theory for several topics which will be applied during the face-to-face course.

During the course each participant will create and share a pharmacovigilance development plan, which will be followed up six months after the course.

The course programme includes social activities such as an official course dinner and an ‘open house’ at the UMC office, providing the opportunity to interact with UMC staff, faculty experts and fellow course participants.

Interested?
This course is tailored for representatives of national and regional pharmacovigilance centres and is also suitable for representatives of public health programmes. Participants are expected to actively contribute to discussions in English and have experience in the pharmacovigilance field.

How to apply?
Please submit your application via the electronic form available on the UMC website (www.who-umc.org) by 12 January 2020. We encourage you to start the application process as soon as possible since we will accept applicants continuously.

The goal of UMC’s admissions review process is to select a maximum of 30 individuals involved in a national pharmacovigilance network who can contribute actively during the course.

Course fee
The course fee is 33,000 SEK. It includes accommodation, breakfast, lunches during course days, course material and social activities. Air fares, per diem, health insurance and all other associated costs are the responsibility of each participant or sponsoring organization.

Venue
The course venue is Hotel Scandic Uplandia in the city of Uppsala, 70 km from Stockholm and 35 km from Arlanda international airport. Uppsala is Sweden’s fourth largest city and home to over 200,000 people.

Questions?
If you have questions, please visit our website: www.who-umc.org or contact the course management via e-mail: pvtraining@who-umc.org

We look forward to welcoming you to Uppsala!
Uppsala Monitoring Centre (UMC) advances the science of pharmacovigilance and inspires patient safety initiatives all over the world. As an independent, non-profit foundation, UMC engages stakeholders who share their vision and collaborates to build a global patient safety culture. As a leader in the research and development of new scientific methods, UMC explores the benefits and risks of medicines to help minimise harm to patients, and offers products and services used by health authorities and life-science companies worldwide. For more than 40 years, UMC has provided scientific leadership and operational support to the WHO Programme for International Drug Monitoring.